Roivant Sciences Ltd.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $95.3M | $-151.1M | $5.10B | $-304.3M | $-291.8M | $-33.6M | $-352.0M | $-291.6M |
| Depreciation & Amortization | $4.9M | $5.2M | $5.4M | $5.6M | $5.8M | $6.0M | $5.2M | $5.1M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $50.2M | $46.7M | $54.3M | $49.3M | $49.3M | $25.3M | $57.7M | $62.0M |
| Net Cash from Operating Activities | $-192.8M | $-108.5M | $-210.5M | $-196.4M | $-249.9M | $-179.1M | $-222.6M | $-189.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $965.0K | $349.0K | $355.0K | $275.0K | $403.0K | $1.6M | $508.0K | $3.1M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-965.0K | $6.9M | $5.23B | $-36.5M | $105.0K | $113.6M | $-3.5M | $-146.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $648.4M | $0 | $0 | $0 | $0 | — | — | — |
| Net Cash from Financing Activities | $-660.6M | $-32.6M | $236.6M | $207.9M | $7.5M | $210.3M | $154.5M | $-7.3M |
| Net Change in Cash | $-857.2M | $-135.0M | $5.26B | $-26.5M | $-242.5M | $151.1M | $-71.6M | $-343.8M |
| Free Cash Flow | $-193.8M | $-108.8M | $-210.8M | $-196.7M | $-250.3M | $-180.7M | $-223.1M | $-192.7M |